JP2013530237A5 - - Google Patents

Download PDF

Info

Publication number
JP2013530237A5
JP2013530237A5 JP2013518685A JP2013518685A JP2013530237A5 JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5 JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5
Authority
JP
Japan
Prior art keywords
group
salt
compound
following groups
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518685A
Other languages
English (en)
Japanese (ja)
Other versions
JP5799479B2 (ja
JP2013530237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042507 external-priority patent/WO2012006202A1/en
Publication of JP2013530237A publication Critical patent/JP2013530237A/ja
Publication of JP2013530237A5 publication Critical patent/JP2013530237A5/ja
Application granted granted Critical
Publication of JP5799479B2 publication Critical patent/JP5799479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518685A 2010-07-07 2011-06-30 Rhoキナーゼインヒビター Active JP5799479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36203610P 2010-07-07 2010-07-07
US61/362,036 2010-07-07
PCT/US2011/042507 WO2012006202A1 (en) 2010-07-07 2011-06-30 Rho kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013530237A JP2013530237A (ja) 2013-07-25
JP2013530237A5 true JP2013530237A5 (enExample) 2014-08-14
JP5799479B2 JP5799479B2 (ja) 2015-10-28

Family

ID=44514975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518685A Active JP5799479B2 (ja) 2010-07-07 2011-06-30 Rhoキナーゼインヒビター

Country Status (4)

Country Link
US (1) US9079880B2 (enExample)
EP (1) EP2590942B1 (enExample)
JP (1) JP5799479B2 (enExample)
WO (1) WO2012006202A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
SI2903618T1 (sl) 2012-10-05 2022-09-30 Kadmon Corporation, Llc Zaviralci RHO kinaze
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
EP3183248B1 (en) 2014-08-21 2020-11-11 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) * 2016-06-21 2022-01-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
JP6948398B2 (ja) * 2016-10-24 2021-10-13 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物
US10738007B2 (en) 2016-10-24 2020-08-11 Translation Drug Development, LLC Amide compounds as kinase inhibitors, compositions and methods of treatment
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
US11168083B2 (en) * 2017-08-04 2021-11-09 Takeda Pharmaceutical Company Limited Inhibitors of Plasma Kallikrein and uses thereof
IL273428B2 (en) 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
CN107903185B (zh) * 2017-11-08 2020-05-26 四川大学 新型eEF2K抑制剂的制备及应用
SMT202400203T1 (it) 2017-11-24 2024-07-09 Jubilant Episcribe Llc Composti eterociclici come inibitori di prmt5
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
WO2019210008A1 (en) * 2018-04-24 2019-10-31 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516384B2 (ja) * 1987-11-27 1996-07-24 保土谷化学工業株式会社 ペンズアミド誘導体
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20020127605A1 (en) 2000-11-28 2002-09-12 Hamilton Gregory S. Bisubstituted carbocyclic cyclophilin binding compounds and their use
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10250743A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
AR051202A1 (es) 2004-09-20 2006-12-27 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US20080009477A1 (en) 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
CN101842357A (zh) 2007-08-30 2010-09-22 武田药品工业株式会社 取代的吡唑衍生物
WO2009065131A1 (en) 2007-11-16 2009-05-22 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
UY31736A (es) 2008-03-26 2009-11-10 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2013530237A5 (enExample)
JP2013531013A5 (enExample)
JP2013544797A5 (enExample)
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
JP2019520396A5 (enExample)
JP2014533259A5 (enExample)
JP2019517475A5 (enExample)
JP2016510032A5 (enExample)
JP2016510033A5 (enExample)
AU2016214492B2 (en) 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
ES2732902T3 (es) Bencimidazol-2-aminas como inhibidores de MIDH1
JP2013056930A5 (enExample)
JP2019520402A5 (enExample)
JP2018517731A5 (enExample)
JP2018501285A5 (enExample)
JP2009502830A5 (enExample)
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2012107706A8 (en) Phenothiazine diaminium salts and their use
JP2018507877A5 (enExample)
JP2014521653A5 (enExample)
JP2010529134A5 (enExample)
JP2014514360A5 (enExample)
JP2010504351A5 (enExample)
JP2016505042A5 (enExample)
JP2015510942A5 (enExample)